Clene's CNM-Au8 Shows Significant Reduction In Neurodegenerative Biomarker, Raises $40M Via Equity
Portfolio Pulse from Vandana Singh
Clene Inc (NASDAQ:CLNN) reported new data showing a significant reduction in plasma neurofilament light chain (NfL) levels for CNM-Au8 treated participants compared to placebo after 24 weeks in the HEALEY ALS Platform Trial. Clene also raised $40 million through an underwritten public offering of 50 million shares and two tranches of warrants at a combined price of $0.80.
June 16, 2023 | 5:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene Inc's CNM-Au8 treatment showed significant reduction in NfL levels, a key biomarker of neurodegeneration, in the HEALEY ALS Platform Trial. The company raised $40 million through an equity offering.
The positive results from the HEALEY ALS Platform Trial indicate that Clene's CNM-Au8 treatment has potential in treating neurodegenerative diseases. This could lead to increased interest and investment in the company. Additionally, the $40 million raised through the equity offering will provide Clene with more resources to further develop and commercialize its products, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100